Fractyl Health, Inc. Common Stock Total Liabilities
Fractyl Health, Inc. Common Stock total liabilities. Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has total liabilities worth $83.64 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Fractyl Health, Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Fractyl Health, Inc. Common Stock (2019–2025)
Total liabilities of Fractyl Health, Inc. Common Stock from 2019 to 2025. This chart illustrates how Fractyl Health, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Fractyl Health, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DAM CAPITAL ADVISORS LTD
NSE:DAMCAPITAL
|
India | Rs1.73 Billion |
|
Carbios
PA:ALCRB
|
France | €65.53 Million |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
Spain | €101.27 Million |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
USA | $26.24 Million |
|
The Joint Corp
NASDAQ:JYNT
|
USA | $35.75 Million |
|
Daesung Ind
KO:128820
|
Korea | ₩1.11 Trillion |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
USA | $68.49 Million |
|
Libstar Holdings Ltd
JSE:LBR
|
South Africa | ZAC4.02 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Fractyl Health, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Fractyl Health, Inc. Common Stock's balance sheet.
Liquidity & Leverage Metrics
Fractyl Health, Inc. Common Stock Total Liabilities Ratios Explained
Fractyl Health, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -50.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fractyl Health, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Fractyl Health, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $111.94 Million | +40.54% |
| 2024-09-30 | $79.65 Million | -80.15% |
| 2023-09-30 | $401.27 Million | +28.09% |
| 2022-09-30 | $313.27 Million | +0.45% |
| 2021-09-30 | $311.87 Million | +1474.40% |
| 2020-09-30 | $19.81 Million | -87.05% |
| 2019-09-30 | $152.93 Million | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more